ClinicalTrials.gg
WithdrawnNCT01882712Updated Nov 6, 2014

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema

A Phase 3 interventional study of CD07805/47 Gel 0.5% and CD07805/47 Gel Placebo in Erythema, sponsored by Galderma R&D. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-06.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily for 29 days versus vehicle control, in subjects with moderate to severe chronic persistent vascular facial erythema

02

Conditions studied

  • Erythema

Browse trials for

03

In context

Erythema

131 studies on the registry are indexed under Erythema; 17 are open to participants now.

Browse Erythema studies →

Lead sponsor

Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, who is at least 18 years of age or older at screening visit.
  • Presence of chronic persistent vascular facial erythema for ≥ 3 months by history.
  • A Clinician's Erythema Assessment (CEA) score of ≥3 at Screening and at Pre-dose (T0) on Baseline/Day 1.
  • A Patient Self Assessment (PSA) score of ≥3 at Screening and at Pre-dose (T0) on Baseline/Day 1.

Exclusion criteria

Exclusion Criteria:

  • More than 2 facial inflammatory lesions (papules, pustules, and nodules).
  • Presence of areas of significant scaling or crusting on the face.
  • Presence of psoriatic lesions on the face.
  • Presence of any other dermatological condition of the face that, in the opinion of the Investigator, may significantly interfere with the interpretation of the clinical trial results.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    CD07805/47 Gel 0.5%

    active arm

    Drug: CD07805/47 Gel 0.5%

  • Placebo comparator
    CD07805/47 Gel Placebo

    Comparator arm

    Drug: CD07805/47 Gel Placebo

Interventions

  • DrugCD07805/47 Gel 0.5%

    Drug page: Brimonidine

  • DrugCD07805/47 Gel Placebo
06

What researchers measure

Primary outcomes

  1. Composite success on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment)

    2-grade improvement on both CEA and PSA at Hours 3, and 6 after Pre-dose (T0)on Day 29

    Time frame: Day 29

Secondary outcomes

  1. Composite improvement on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment)

    1-grade improvement on both CEA and PSA at 30 minutes after pre-dose (T0) on Day 1

    Time frame: Day 1

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01882712
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 20, 2013
Primary completion
Sep 2015 (estimated)
Last update
Nov 6, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion